Skip to main content

3 Result(s)

within Thomas Freude Remove this filter Biomedicine, general Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    BMP9 a possible alternative drug for the recently withdrawn BMP7? New perspectives for (re-)implementation by personalized medicine

    Promotion of rhBMP2 and rhBMP7 for the routine use to support fracture healing has been hampered by high costs, safety concerns and reasonable failure rates, imposing restrictions in its clinical use. Since th...

    Vrinda Sreekumar, Romina Haydeé Aspera-Werz, Gauri Tendulkar… in Archives of Toxicology (2017)

  2. No Access

    Article

    Chronic CCl4 intoxication causes liver and bone damage similar to the human pathology of hepatic osteodystrophy: a mouse model to analyse the liver–bone axis

    Patients with chronic liver diseases frequently exhibit decreased bone mineral densities (BMD), which is defined as hepatic osteodystrophy (HOD). HOD is a multifactorial disease whose regulatory mechanisms ar...

    Andreas K. Nussler, Britt Wildemann, Thomas Freude… in Archives of Toxicology (2014)

  3. No Access

    Article

    Darbepoetin inhibits proliferation of hepatic cancer cells in the presence of TGF-β

    Darbepoetin (DPO), an erythropoietin (EPO) derivative, was licensed in 2002 to treat patients with solid tumors suffering from chemotherapy-dependent anemia, although various tumors express EPO to improve vasc...

    Sabrina Ehnert, Thomas Freude, Carmen Eicher, Britta Burkhardt… in Archives of Toxicology (2014)